Volpara Health Technologies, the Kiwi digital health firm listed on the ASX, narrowed its first-half loss as rising revenue put it on track to deliver faster sales growth through the remainder of the year.
The Wellington-based company yesterday reported a loss of $4.2 million, or 3 cents per share, in the six months ended September 30, from a loss of $4.7 million, or 4 cents, a year earlier.
Volpara lifted revenue 41 per cent to $1.7 million with commercial sales up 13 per cent to $1.3 million and the balance from increased research and development government grants.
On an annualised recurring revenue basis, a favoured measure for software-as-a-service firms, sales rose 94 per cent to $2.1 million.
"This puts the company on track to exceed its 200 per cent growth target for FY18, given H2 is typically strong than H1," chief executive Ralph Highnam said in a statement to the ASX.